Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tilo Grosser

Showing results (1-10 of 72) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|April 6, 2017
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for ArthritisTilo Grosser
Thrombosis and Haemostasis|September 28, 2006
The pharmacology of selective inhibition of COX-2Tilo Grosser
Blood|May 30, 2015
microRNA represses macromoleculeTilo Grosser
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 16, 2009
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapyTilo Grosser
Hematology. American Society of Hematology. Education Program|November 24, 2005
The cardiovascular pharmacology of COX-2 inhibitionSusanne Fries, Tilo Grosser
Clinical Pharmacology and Therapeutics|February 15, 2022
Mechanism of Variability in the Response to Low Dose AspirinSusanne Fries, Tilo Grosser
Lancet (London, England)|July 19, 2018
Weight-adjusted aspirin for cardiovascular preventionKatherine N Theken, Tilo Grosser
Archives of Physiology and Biochemistry|November 17, 2009
Elective affinities--bioinformatic analysis of proteomic mass spectrometry dataXuanwen Li, Angel Pizarro, Tilo Grosser
Prostaglandins & Other Lipid Mediators|September 18, 2012
Prostanoids and inflammatory painLihong Chen, Guangrui Yang, Tilo Grosser
The Journal of Clinical Investigation|January 6, 2006
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesTilo Grosser, Susanne Fries, Garret A FitzGerald
Pageof 8

Showing results (1-10 of 72) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|April 6, 2017
Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for ArthritisTilo Grosser
Thrombosis and Haemostasis|September 28, 2006
The pharmacology of selective inhibition of COX-2Tilo Grosser
Blood|May 30, 2015
microRNA represses macromoleculeTilo Grosser
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|July 16, 2009
Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapyTilo Grosser
Hematology. American Society of Hematology. Education Program|November 24, 2005
The cardiovascular pharmacology of COX-2 inhibitionSusanne Fries, Tilo Grosser
Clinical Pharmacology and Therapeutics|February 15, 2022
Mechanism of Variability in the Response to Low Dose AspirinSusanne Fries, Tilo Grosser
Lancet (London, England)|July 19, 2018
Weight-adjusted aspirin for cardiovascular preventionKatherine N Theken, Tilo Grosser
Archives of Physiology and Biochemistry|November 17, 2009
Elective affinities--bioinformatic analysis of proteomic mass spectrometry dataXuanwen Li, Angel Pizarro, Tilo Grosser
Prostaglandins & Other Lipid Mediators|September 18, 2012
Prostanoids and inflammatory painLihong Chen, Guangrui Yang, Tilo Grosser
The Journal of Clinical Investigation|January 6, 2006
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunitiesTilo Grosser, Susanne Fries, Garret A FitzGerald
Pageof 8